Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria

Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria Dear Editor,Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU). While antihistamines and omalizumab are effective treatments for both CSU and ColdU, many patients show insufficient response to either or both of these treatments, and additional and better therapies are needed.Reslizumab is a humanized monoclonal anti‐interleukin 5 (IL‐5) antibody licensed for the treatment of severe eosinophilic asthma. IL‐5 is the major cytokine responsible for the recruitment, activation and survival of eosinophils, which play a crucial role in causing tissue and subsequent airway hyperresponsiveness in asthma. Previously, we demonstrated that eosinophil numbers are increased in the skin of CSU patients. Recently, we reported that treatment with mepolizumab, another monoclonal antibody against IL‐5, can result in the rapid remission of CSU.Here, we report the case of a 43‐year‐old woman with severe non‐allergic refractory eosinophilic asthma (non‐smoker, IgE 136 kU/L, skin prick test negative to pollen, mites and other common aeroallergens, eosinophils 540/μL, FEV1 75% predicted, asthma control test (ACT) 15 points, four asthma exacerbations in the last year, therapy including prednisolone 50–25 mg/day, LAMA and LABA) who was successfully treated for her asthma with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria

Loading next page...
 
/lp/wiley/benefit-from-reslizumab-treatment-in-a-patient-with-chronic-VmYxa4zKmC
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14594
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU). While antihistamines and omalizumab are effective treatments for both CSU and ColdU, many patients show insufficient response to either or both of these treatments, and additional and better therapies are needed.Reslizumab is a humanized monoclonal anti‐interleukin 5 (IL‐5) antibody licensed for the treatment of severe eosinophilic asthma. IL‐5 is the major cytokine responsible for the recruitment, activation and survival of eosinophils, which play a crucial role in causing tissue and subsequent airway hyperresponsiveness in asthma. Previously, we demonstrated that eosinophil numbers are increased in the skin of CSU patients. Recently, we reported that treatment with mepolizumab, another monoclonal antibody against IL‐5, can result in the rapid remission of CSU.Here, we report the case of a 43‐year‐old woman with severe non‐allergic refractory eosinophilic asthma (non‐smoker, IgE 136 kU/L, skin prick test negative to pollen, mites and other common aeroallergens, eosinophils 540/μL, FEV1 75% predicted, asthma control test (ACT) 15 points, four asthma exacerbations in the last year, therapy including prednisolone 50–25 mg/day, LAMA and LABA) who was successfully treated for her asthma with

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial